In vitro effects of three blood derivatives on human corneal epithelial cells

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5571-5578

  Freire, Vanesa ^a   Andollo, Noelia ^b   Etxebarria, Jaime ^b,c   Durán, Juan A ^a,b   Morales, María Celia ^a  

^a Instituto Clínico Quirúrgico de Oftalmología   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BLOOD DERIVATIVE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GAP JUNCTION PROTEIN; INVOLUCRIN; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; SIGNAL PEPTIDE;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CORNEA CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; THROMBOCYTE RICH PLASMA; ADULT; CELL DIFFERENTIATION; CELL LINE; COMPARATIVE STUDY; CORNEA EPITHELIUM; CYTOLOGY; MIDDLE AGED; PHYSIOLOGY;

ADULT; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; EPITHELIUM, CORNEAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PLATELET-RICH PLASMA; SERUM;

EID: 84867908648     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7340     Document Type: Article

References (58)

1. Cavanagh HD, Colley AM. The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl. 1989;192:115-134.
2. Ladas JG, Mondino BJ. Systemic disorders associated with peripheral corneal ulceration. Curr Opin Ophthalmol. 2000; 11:468-471.
3. Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role in tissue maintenance, wound healing and ocular pathology. Ocul Surf. 2007;5:228-239.
4. Geerling G, Daniels JT, Dart JK, Cree IA, Khaw PT. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:948-956.
5. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
6. Lambiase A, Centofanti M, Micera A, et al. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 1997;235:780-785.
7. Lambiase A, Coassin M, Sposato V, et al. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol Res. 2007;56:65-69.
8. Dellaert MM, Casey TA, Wiffen S, et al. Influence of topical human epidermal growth factor on postkeratoplasty reepithelialisation. Br J Ophthalmol. 1997;81:391-395.
9. Gordon JF, Johnson P, Musch DC. Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group. Am J Ophthalmol. 1995;119:281-287.
10. Slater M, Patava J, Kingham K, Mason RS. Involvement of platelets in stimulating osteogenic activity. J Orthop Res. 1995; 13:655-663.
11. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459-461.
12. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol. 1999;83:390-395.
13. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984-1989.
14. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20:807-810.
15. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eye and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001; 85:1188-1197.
16. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111:1115-1120.
17. López-García JS, García-Lozano I, Rivas L, et al. Use of autologous serum in ophthalmic practice. Arch Soc Esp Oftalmol. 2007;82:9-20.
18. Hartwig D, Harloff S, Liu L, Schlenke P, Wedel T, Geerling G. Epitheliotrophic capacity of a growth factor preparation produced from platelet concentrates on corneal epithelial cells: a potential agent for the treatment of ocular surface defects? Transfusion. 2004;44:1724-1731.
19. Dohan Ehrenfest DM. Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27:158-167.
20. Vajpayee RB, Mukerji N, Tandon R, et al. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol. 2003;87:1312-1316.
21. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114:1502-1508.
22. Liu L, Hartwig D, Harloff S, et al. Corneal epitheliotrophic capacity of three different blood-derived preparations. Invest Ophthalmol Vis Sci. 2006;47:2438-2444.
23. Everts PA, Brown Mahoney C, Hoffmann JJ, et al. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors. 2006;24:165-171.
24. Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39:124-129.
25. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006;32(suppl 1):98-110.
26. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529-535.
27. Anitua E, Andía I, Sánchez M, et al. Autologous preparation rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthopaedic Res. 2005;23:281-286.
28. López-Plandolit S, Morales MC, Freire V, Etxebarría J, Durán JA. Plasma rich in growth factors as a therapeutic agent for persistent corneal epithelial defects. Cornea. 2010;29:843-848.
29. López-Plandolit S, Morales MC, Freire V, Grau AE, Durán JA. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea. 2011;30:1312-1317.
30. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
31. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
32. Greenhalgh DG. The role of growth factors in wound healing. J Trauma. 1996;41:159-167.
33. Giannobile WV. Periodontal tissue engineering by growth factors. Bone. 1996;19(suppl 1):23S-37S.
34. Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg. 1997;55:1294-1299.
35. Dugrillon A, Eichler H, Kern S, Klüter H. Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. Int J Oral Maxillofac Surg. 2002;31: 615-619.
36. Trindade-Suedam IK, Leite FR, de Morais JA, Leite ER, Marcantonio EJ, Leite AA. Avoiding leukocyte contamination and early platelet activation in platelet-rich plasma. J Oral Implantol. 2007;33:334-339.
37. Anitua A, Sanchez M, Zalduendo MM, et al. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009;42:162-170.
38. Kitazawa T, Kinoshita S, Fujita K, et al. The mechanism of accelerated corneal epithelial healing by human epidermal growth factor. Invest Ophthalmol Vis Sci. 1990;31:1773-1778.
39. Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci. 1997;110 (Pt 2):113-121.
40. Anitua E, Sanchez M, Nurden AT, et al. Reciprocal actions of platelet-secreted TGF-beta1 on the production of VEGF and HGF by human tendon cells. Plast Reconstr Surg. 2007;119: 950-959.
41. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003;33:381-394.
42. Stepp MA, Spurr-Michaud S, Gipson IK. Integrins in the wounded and unwounded stratified squamous epithelium of the cornea. Invest Ophthalmol Vis Sci. 1993;34:1829-1844.
43. Ratkay-Traub I, Hopp B, Bor Z, Dux L, Becker DL, Krenacs T. Regeneration of rabbit cornea following excimer laser photorefractive keratectomy: a study on gap junctions, epithelial junctions and epidermal growth factor receptor expression in correlation with cell proliferation. Exp Eye Res. 2001;73:291-302.
44. Shurman DL, Glazewski L, Gumpert A, Zieske JD, Richard G. In vivo and in vitro expression of connexins in the human corneal epithelium. Invest Ophthalmol Vis Sci. 2005;46:1957-1965.
45. Gipson IK. Adhesive mechanisms of the corneal epithelium. Acta Ophthalmol Suppl. 1992;202:13-17.
46. Scott RA, Lauweryns B, Snead DM, Haynes RJ, Mahida Y, Dua HS. E-cadherin distribution and epithelial basement membrane characteristics of the normal human conjunctiva and cornea. Eye. 1997;11 (Pt 5):607-612.
47. Suzuki K, Tanaka T, Enoki M, Nishida T. Coordinated reassembly of the basement membrane and junctional proteins during corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2000;41:2495-2500.
48. Ban Y, Dota A, Cooper LJ, et al. Tight junction-related protein expression and distribution in human corneal epithelium. Exp Eye Res. 2003;76:663-669.
49. Kimura K, Teranishi S, Nishida T. Establishment of human corneal epithelial cells stably expressing human connexin43. Exp Eye Res. 2010;90:4-9.
50. Chen Z, de Paiva CS, Luo L, Kretzer FL, Pflugfelder SC, Li DQ. Characterization of putative stem cell phenotype in human limbal epithelia. Stem Cells. 2004;22:355-366.
51. Micallef L, Belaubre F, Pinon A, et al. Effects of extracellular calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells compared with normal human keratinocytes. Exp Dermatol. 2009;18:143-151.
52. Gibson DF, Bikle DD, Harris J, Goldberg GS. The expression of the gap junctional protein Cx43 is restricted to proliferating and non differentiated normal and transformed keratinocytes. Exp Dermatol. 1997;6:167-174.
53. Matic M, Petrov IN, Rosenfeld T, Wolosin JM. Alterations in connexin expression and cell communication in healing corneal epithelium. Invest Ophthalmol Vis Sci. 1997;38:600-609.
54. Nakano Y, Oyamada M, Dai P, Nakagami T, Kinoshita S, Takamatsu T. Connexin43 knockdown accelerates wound healing but inhibits mesenchymal transition after corneal endothelial injury in vivo. Invest Ophthalmol Vis Sci. 2008;49: 93-104.
55. Schlötzer-Schrehardt U, Kruse FE. Identification and characterization of limbal stem cells. Exp Eye Res. 2005;81:247-264.
56. Gipson IK, Spurr-Michaud S, Tisdale A, Elwell J, Stepp MA. Redistribution of the hemidesmosome components alpha 6 beta 4 integrin and bullous pemphigoid antigens during epithelial wound healing. Exp Cell Res. 1993;207:86-98.
57. Laux-Fenton WT, Donaldson PJ, Kistler J, Green CR. Connexin expression patterns in the rat cornea: molecular evidence for communication compartments. Cornea. 2003;22:457-464.
58. Brissette JL, Kumar NM, Gilula NB, Hall JE, Dotto GP. Switch in gap junction protein expression is associated with selective changes in junctional permeability during keratinocyte differentiation. Proc Natl Acad Sci U S A. 1994;91:6453-6457.